Read the lates neuroCare Group News here
New CE identification number for neuroConn medical devices
As of today, 8 August 2015, the following medical devices of neuroConn GmbH
- THERA PRAX®
- NEURO PRAX®
are certified with the identification number CE 0123 of the Notified Body TÜV SÜD Product Service GmbH, Munich, Germany.
University of Salzburg: Brain training instead of medication to counter insomnia
Austrian researchers of the University of Salzburg found in a pilot study that Neurofeedback training of the sensorimotor rhythm helps people with primary insomnia. In 16 out of 24 participants the training of this particular brain wave rhythm during waking state resulted not only in better quality of the sleep, but also in improved memory consolidation during sleep. The researchers used the THERA PRAX® for the study.
The sensorimotor rhythm is a rhythm of brain oscillations ranging from 12 to 15 hertz and is prominent in light sleep and when a person is falling asleep.
Study published: Neurofeedback improves impulsive and aggressive behavior in psychopathic offenders
Neurofeedback enables psychopathic individuals are able to learn to self-regulate the activity of particular fronto-central brain areas involved in emotional evaluation and behavioral control. This is the result of a first study conducted by researchers of the University of Tübingen, Germany, investigating the effects of Neurofeedback training on disinhibition, aggression, and antisocial behavior in severe criminal psychopaths.
The researches recruited 14 male psychopathic offenders serving long term sentences in forensic psychiatric institutions, who underwent 25 sessions of training of the slow cortical potentials. The participants of the study showed improved behavioral control and behavioral regulation as well as improved inhibition of impulsive and aggressive behavior. Further studies with larger samples and more adequate control conditions are recommended.read publication
FDA recognizes IEEE standard for neurofeedback devices
The Food and Drug Association (FDA) of the USA lists under new entries of recognized standards: IEEE Std 2010-2012 Practice for Neurofeedback Systems.
Read FDA announcement (standard 17-13, IEEE Recommended Practice for Neurofeedback Systems, IEEE Std 2010-2012)
This industrial standard was issued in May 2012 by IEEE (Institute of Electrical and Electronics Engineers) as a collaboration of various manufacturers of neurofeedback devices, the International Society for Neurofeedback and Research (ISNR) and FDA. It enables manufacturers to describe basic components and functions of their neurofeedback systems. On the other hand it allows the users to compare the systems of different manufacturers. Our company had contributed to setting up this standard by providing our input of then over 10 years of experience in the development of neurofeedback devices.
Electric current stimulation in Glaucoma treatment
The electric current therapy stimulates the nerves in the visual cortex. The hope is to improve the brains abilitiy to interprete the data coming in through the damaged optic nerve and thus to repair damaged areas in the visual field. The therapy takes several sessions of 30 minutes during which the neuroConn DC-STIMULATOR MC applies weak electrical impulses via an electrode placed over the closed eye.
Watch broadcast by German TV station showing the DC-STIMULATOR MC (German - "Mit Wechselstrom besser sehen").
Watch broadcast by University of Magdeburg (from 2012)
Neurofeedback und NIRS for ADHD
In the past we mainly reported about training of the slow cortical potentials for ADHD. The Tübingen University shows in a video (German) a new approach which they are investigating in adult ADHD patients. Here they combine the THERA PRAX® neurofeedback system with near-infrared spectroscopy (NIRS).
In the NIRS neurofeedback oxygenated hemoglobin in the prefrontal cortex is measured and fed back. The patient is required to increase or decrease hemodynamic activity in the investigated cortex. The researches hope that this method increases the attention.
Pictures: Oliver Koll, Thanh Mai - CampusTVwatch video (German)
SCP training causes sustained reduction of epileptic seizures
Even more than 10 years after completion of a controlled clinical trial on SCP training in intractable epilepsie, those participants, who had taken part in the follow-up evaluation, were still able to control their SCPs during the feedback condition. Even more, there was a significant decrease in seizure frequency 10 years after the end of the neurofeedback training.
Besides the very small sample size in the follow-up evaluation, the scientists conclude that SCP training may be considered as a treatment for patients with intractable epilepsie and as an adjunct to conventional therapy.
Read study in PubMed
Safety of medicines used for ADHD in children
A metaanalysis of several studies on the long-term safety of drugs for ADHD with a total of over 2,200 children and adolescents reveals, that side effects are not rare. Between 58 and 78% of all participants reported Adverse Events (AEs), most commonly decreased appetite, insomnia, headache and abdominal pain. Up to one quarter of the patients discontinued due to AEs.Abstract
Surmounting retraining limits in Musicians' dystonia by transcranial stimulation
The study tested whether skilled finger movements can be restored in musicians with focal hand dystonia through behavioral training assisted by transcranial direct current stimulation to the motor cortex of both hemispheres.They found improvement in the rhythmic accuracy of sequential finger movements with the affected hand during and after cathodal stimulation over the affected cortex and simultaneous anodal stimulation over the unaffected cortex. The improvement was retained 4 days after intervention.Abstract
Abstract in PubMed: Shaping memory accuracy by left prefrontal transcranial direct current stimulation.
See also Amelioration of cognitive control in depression by transcranial direct current stimulation. published in Biological Psychiatry in April 2013
Rogue Research Inc. and neuroConn GmbH agree to create a new joint venture to implement an integrated product strategy.
Rogue Research Inc. and neuroConn GmbH are pleased to announce an agreement to form a joint venture to promote a new line of integrated products to the neuroscience and neurology research communities. The new company, Rogue Resolutions based in Cardiff, UK, will be run by Andrew Thomas and Dan Philips, both with over 16 years of experience in the field of neuroscience between them.
Over the last few years, we have been approached by many of our customers who desire a more integrated approach in configuring the various pieces of equipment in the laboratory. We are answering that call with a bold step in both product design and in how we market our products. Rogue Resolutions will coordinate development, marketing, sales and support of a new line of products designed to work seamlessly with each other and consolidate user interface to simplify complex experiments and add new capabilities.
These design principles will be mirrored in our sales and support by providing a single point of entry for the customer for all our products going forward. Customers looking to perform complex experiments with our equipment will benefit by having access to technical expertise in each product as well as in configuring them to work together effectively.
As we implement this new strategy, we will continue to honour purchases through our longtime partner, The Magstim Company. We now assume all customer support responsibilities for all Brainsight products worldwide. If you purchased your equipment from a distributor, please direct all future customer support enquiries directly to Rogue Research (firstname.lastname@example.org) or neuroConn (email@example.com). If you have received a quotation from a distributor recently, please contact us directly for a new quotation at firstname.lastname@example.org.